AC Immune vs Annovis Bio
ACIU and ANVS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACIU and ANVS compare
Annovis Bio scores higher on the StockData Score (4 against 3 for AC Immune), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACIU | ANVS |
|---|---|---|
| Size and price | ||
| Market cap | – | $39.5M |
| Share price | $2.13 | $0.926 |
| Change, 1 year | −35.1% | −61.9% |
| Change, 5 years | −61.1% | −96.6% |
| Beta (5Y) | 1.17 | 1.95 |
| Employees | 122 | 8 |
| StockData Score | ||
| Total score | 3 | 4 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 3 | 4 (better) |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −86.9% | – |
| Revenue growth, 5Y average | −25.4% | – |
| Profitability | ||
| Operating margin | −1940% | – |
| FCF margin | −1964% | – |
| Financial health | ||
| Interest coverage | −362.9× | – |
| Current ratio | 0.93 | – |
| Altman Z-score | – | −86.45 |
| Piotroski F-score | – | 3 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | – | 25.5% |
| Held by insiders | 23.6% | 23.1% |
| Insider net buying, 12 months | −$27.9K | $6.8M (better) |
| Short interest, % of float | – | 16.3% |
Go deeper
- ACIU stock overview
- ACIU income statement
- ACIU valuation and score
- ANVS stock overview
- ANVS income statement
- ANVS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.